All In Biotech

Drug Trial Radar · NCT03924856

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866)

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 907 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

907

Actual

Start

Jun 13, 2019

Primary completion

Jan 26, 2026

Study completion May 18, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

Conditions

  • Bladder Cancer

Interventions

  • PembrolizumabDrug

    Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle

  • GemcitabineDrug

    Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle

  • CisplatinDrug

    Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle

  • Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])Procedure

    Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.

  • PlaceboDrug

    Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-Free Survival (EFS)Time frame: Up to approximately 60 months

Locations

175 sites in 22 countries. Site status is shown where the registry gives one.

  • Scripps MD Anderson ( Site 0010)

    La Jolla, California

  • Providence Saint John's Health Center ( Site 0075)

    Santa Monica, California

  • Georgetown University Medical Center ( Site 0022)

    Washington D.C., District of Columbia

  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0005)

    Orlando, Florida

  • Parkview Cancer Institute ( Site 0077)

    Fort Wayne, Indiana

  • Indiana University Melvin and Bren Simon Cancer Center ( Site 0004)

    Indianapolis, Indiana

  • Ochsner Medical Center ( Site 0049)

    New Orleans, Louisiana

  • New England Cancer Specialists ( Site 0070)

    Scarborough, Maine

  • UMass Memorial Medical Center ( Site 0051)

    Worcester, Massachusetts

  • Henry Ford Hospital ( Site 0039)

    Detroit, Michigan

  • Mercy Hospital Saint Louis ( Site 0064)

    St Louis, Missouri

  • Morristown Medical Center ( Site 0015)

    Morristown, New Jersey

  • UNM Comprehensive Cancer Center-Clinical Research Office ( Site 0045)

    Albuquerque, New Mexico

  • New York University Perlmutter Cancer Center ( Site 0008)

    New York, New York

  • University Hospitals Cleveland Medical Center ( Site 0038)

    Cleveland, Ohio

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021)

    Tulsa, Oklahoma

  • Portland VA Medical Center ( Site 0084)

    Portland, Oregon

  • Allegheny General Hospital ( Site 0048)

    Pittsburgh, Pennsylvania

  • MD Anderson Cancer Center ( Site 0063)

    Houston, Texas

  • Central Texas Veterans Healthcare System ( Site 0057)

    Temple, Texas

  • Inova Schar Cancer Institute ( Site 0007)

    Fairfax, Virginia

  • Northwest Medical Specialties, PLLC ( Site 0061)

    Puyallup, Washington

  • Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033)

    Seattle, Washington

  • Charleston Area Medical Center ( Site 0023)

    Charles Town, West Virginia

  • Mid North Coast Cancer Institute ( Site 1256)

    Port Macquarie, New South Wales, Australia

  • Southside Cancer Care Centre ( Site 1252)

    Sydney, New South Wales, Australia

  • Cairns Base Hospital ( Site 1257)

    Cairns, Queensland, Australia

  • Eastern Health ( Site 1255)

    Box Hill, Victoria, Australia

  • Peninsula Health Frankston Hospital ( Site 1258)

    Frankston, Victoria, Australia

  • UZ Brussel ( Site 0358)

    Brussels, Bruxelles-Capitale, Region de, Belgium

  • Jessa Ziekenhuis ( Site 0360)

    Hasselt, Limburg, Belgium

  • CHU UCL Namur Site de Godinne ( Site 0354)

    Yvoir, Namur, Belgium

  • O.L.V. Ziekenhuis Aalst ( Site 0356)

    Aalst, Oost-Vlaanderen, Belgium

  • AZ Maria Middelares Gent ( Site 0353)

    Ghent, Oost-Vlaanderen, Belgium

  • Tom Baker Cancer Centre ( Site 0100)

    Calgary, Alberta, Canada

  • Nova Scotia Health Authority ( Site 0109)

    Halifax, Nova Scotia, Canada

  • Kingston Health Sciences Centre ( Site 0103)

    Kingston, Ontario, Canada

  • Lakeridge Health ( Site 0104)

    Oshawa, Ontario, Canada

  • Sunnybrook Research Institute ( Site 0110)

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 0107)

    Toronto, Ontario, Canada

Showing 40 of 175 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.